An overview of the patterns of prescription opioid use, costs and related harms in Australia

Abstract

Aims To report Australian population trends in subsidized prescribed opioid use, total costs to the Australian government to subsidize these medicines and opioid‐related harms based on hospitalizations and accidental poisoning deaths. Methods We utilized three national aggregated data sources including dispensing claims from the Pharmaceutical Benefits Scheme, opioid‐related hospitalizations from the National Hospital Morbidity Database and accidental poisoning deaths from the Australian Bureau of Statistics. Results Between 1992 and 2012, opioid dispensing episodes increased 15‐fold (500 000 to 7.5 million) and the corresponding cost to the Australian government increased 32‐fold ($8.5 million to $271 million). Opioid‐related harms also increased. Opioid‐related hospitalizations increased from 605 to 1464 cases (1998–2009), outnumbering hospitalizations due to heroin poisonings since 2001. Deaths due to accidental poisoning (pharmaceutical opioids and illicit substances combined) increased from 151 to 266 (2002–2011), resulting in a rise in the death rate of 0.78 to 1.19 deaths/100 000 population over 10 years. Death rates increased 1.8 fold in males and 1.4 fold in females. Conclusions The striking increase in opioid use and related harms in Australia is consistent with trends observed in other jurisdictions. Further, there is no evidence to suggest these increases are plateauing. There is currently limited evidence in Australia about individual patterns of opioid use and the associated risk of adverse events. Further research should focus on these important issues so as to provide important evidence supporting effective change in policy and practice.

Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations

“…[6] In most cases, these relatives and friends had obtained their prescriptions from a single doctor. [6] Drivers of prescription opioid abuse have been shown to include increased availability of therapeutic opioids, [7][8][9][10] a history of illicit substance use and abuse or a substance use disorder [11] and comorbid mental health disorders. [12] Societal costs of abuse of prescription opioid analgesics in the USA were estimated to be $55.7 billion in 2007.…”

Prescribing wellness: comprehensive pain management outside specialist services

“…17 Dispensing in Australia increased 15-fold between 1992 and 2012, predominantly reflecting long-term opioid provision for chronic pain. 18 The absence of long-term efficacy data has finally been addressed in a landmark randomised controlled trial of long-term opioids compared to non-opioid medicines for chronic musculoskeletal pain. During a year of collaborative care, the initiation of opioids failed to improve function, but caused more adverse effects and marginally worse pain intensity.…”

Editors' pick 2014

“…Other Western countries are not immune. In a comprehensive analysis of opioid prescribing, harm and costs, Blanch and colleagues [4] reviewed prescribing data from the Australian national subsidized reimbursement medicine scheme. Australia has a staggering 241 different opioid formulations available from 14 opioids.…”